LANSING, MI–November 30, 2010-  Kraig Biocraft Laboratories, Inc. (KBLB) announced today the release of a short video featuring interviews with the Company CEO and a leading member of the scientific team outlining the Company’s technology breakthrough and its commercial potential. The video released today describes the Company’s recent commercial and technological breakthroughs that have garnered the attention of scientific and trade publications.

The six minute video features the Company’s founder and CEO Kim Thompson. “It’s a whole new ball game,” said Thompson. “We’re launching new technologies and as Kraig moves into commercialization of our discoveries, it’s becoming increasingly important to communicate the vision for our technologies. This video is the first of a two part video presentation outlining our achievements and communicating our vision for the immediate future.”

The video, entitled “Kraig KBLB Breakthrough” is available on the video page of the Company website and on YouTube at https://www.youtube.com/watch?v=MDP-kdZU_WQ.

Kraig Biocraft Laboratories is a biotechnology company which recently announced the invention and discovery of a scalable genetic engineering technology for the production of new polymers including recombinant spider silks. To learn more about Kraig Biocraft Laboratories and its recent commercial and scientific breakthroughs please visit www.KraigLabs.com.

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “implications,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel
(720) 288-8495
benh@ttfsco.com

Renowned Former SmithKline & French Laboratories Executive Joins Kraig Advisory Board

LANSING, MI–November 22, 2010- Kraig Biocraft Laboratories, Inc. (KBLB) announced today that Raymond Kutsunai, the former general manager of SmithKline & French Laboratories, Japan, has joined the Company’s Board of Advisors.

Mr. Kutsunai was a central figure in SmithKline & French Laboratories operations and spectacular growth in Japan. Kutsunai is the second former major executive from SmithKline to join Kraig Biocraft Laboratories’ advisory board. Earlier this month SmithKline Beecham’s celebrated former CEO and Chairman Henry Wendt joined the Company’s Board of Advisors. SmithKline Beecham, which became Glaxo SmithKline, is one of the world’s largest and most successful corporations.

“Kraig Biocraft Laboratories is privileged to be able to attract this extraordinary level of talent,” said the Company’s founder and CEO Kim K. Thompson. “We are particularly excited about bringing Mr. Kutsunai onto the team. He rightfully deserves his stellar reputation in Japan for accomplishment and integrity. In addition to his extensive business experience and leadership Mr. Kutsunai also has extensive contacts in Japan which may prove to be invaluable as our Company grows. His proven record for orchestrating and managing explosive growth is exactly what we need as we move to commercialize our technologies.”

Kraig Biocraft Laboratories is a fully reporting biotechnology company, which recently achieved a series of scientific breakthroughs with implications for the global textile industry.

To learn more about Kraig Biocraft Laboratories and its recent commercial and scientific breakthroughs please visit www.KraigLabs.com. The website hosts several short videos describing the Company’s recent commercial and technological breakthroughs and outlines the commercial potential that has garnered attention of many scientific and trade journals.

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “implications,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel
(720) 288-8495
benh@ttfsco.com

LANSING, MI–November 18, 2010- Kraig Biocraft Laboratories, Inc. (KBLB) announces that the Company has submitted its 10Q filing for the third quarter of 2010.

The Company’s financial statements reflect more than a fifty percent reduction in total corporate liabilities in comparison to both the second quarter of 2010 and the 2009 end of year figures. At the end of this year’s second quarter and at the end of 2009, corporate liabilities totaled approximately $3.2 million. The financial statements filed today reflect total liabilities of approximately $1.465 million as of September 30, 2010.

“The reduction of our liabilities and the strengthening of our balance sheet has been a focus of management’s attention, as we move to commercialize our laboratory discoveries,” said Kim Thompson, Kraig Biocraft Laboratories’ CEO and founder. “We view it as a critical component for positioning ourselves for upcoming events and most particularly as we seek corporate alliances to accelerate the entry of our products into the marketplace.”

“In order to contribute to that effort, among other things, I have surrendered most of my unpaid back salary to the Company, along with the beneficial conversion features which would have allowed me to covert that debt to stock on favorable terms,” continued Thompson. “That action, along with other actions we have taken over the last several months have, in my opinion, significantly improved the Company’s financial position and have made us a potentially more attractive partner as we seek out new relationships in both the biotechnology and textiles industries.”

In exchange for the surrendering of back salary, beneficial conversion rights and certain other debts, including the right to certain mile stone payments, the Company will issue to Thompson preferred stock bearing extra voting rights. These shares will not be entitled to any dividends or interest payments whatsoever.

To learn more about the Company’s recent commercial and scientific breakthroughs please visit www.KraigLabs.com.

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel
(720) 288-8495
benh@ttfsco.com

Renowned Fortune 500 CEO Joins Kraig Advisory Board

LANSING, MI–November 9, 2010- Kraig Biocraft Laboratories, Inc. (KBLB) announced today that Henry Wendt, the renowned former head of SmithKline Beecham, has joined the Company’s Board of Advisors.

Wendt is the former CEO and Chairman of SmithKline Beecham, one of the world’s largest and most successful corporations. He has an unparalleled track record for fostering and managing corporate growth through mergers and acquisitions, as well as through organic growth and global marketing. In fact, he is generally recognized as the principal architect of the successful merger which created SmithKline Beecham.

“Henry Wendt is one of the top CEOs on the planet, with a proven Fortune 500 track record,” said Kraig Biocraft Laboratories CEO, Kim K. Thompson. “In addition to his groundbreaking leadership at SmithKline Beecham, he literally wrote the book on successful strategies for corporate growth in the global marketplace. Mr. Wendt’s book Global Embrace: Corporate Challenges in a Transnational World is, in my opinion, a ‘must read’ for corporate executives. We are very fortunate and excited to have him on our team. I know that, as a member of our advisory board, his insight and advice will be invaluable, as we grow and commercialize our revolutionary technologies.”

Kraig Biocraft Laboratories is a fully reporting biotechnology company, which recently achieved a series of scientific breakthroughs with implications for the global textile industry.

To learn more about Kraig Biocraft Laboratories and its recent commercial and scientific breakthroughs please visit www.KraigLabs.com. The website hosts several short videos describing the Company’s recent commercial and technological breakthroughs and outlines the commercial potential that has garnered attention of many scientific and trade journals.

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “implications,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel
(720) 288-8495
benh@ttfsco.com

LANSING, MI–November 4, 2010- Kraig Biocraft Laboratories Inc. (KBLB) announces that Technology Review, published by the Massachusetts Institute of Technology, recently featured the company in its article titled, “Transgenic Worms Make Tough Fibers,” which is available online at http://www.technologyreview.com/biomedicine/26623/.

“MIT’s Technology Review is a very prestigious publication, and we are pleased with the interest in our company,” said Kim Thompson, Kraig Biocraft Laboratories CEO and founder. “The fact that Technology Review featured Kraig’s recent genetic engineering breakthroughs as the headlining story highlights the importance and commercial potential of this new technology. Frankly, our research team has earned these accolades by creating a technology that has the potential to revolutionize material science and have an exciting and positive impact on the textile markets.”

To learn more about company’s recent commercial and scientific breakthrough, visit KraigLabs.com.

The Kraig Labs Web site (www.KraigLabs.com) currently hosts several short videos that describe the technological breakthrough and outlines the commercial potential, which garnered attention in the scientific and trade journals. Also available on the Web site is the company’s recent CEO shareholder conference call.

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research and create commercially-viable products may be affected by the competitive environment, the company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel
(720) 288-8495
benh@ttfsco.com

Kraig Biocraft Laboratories, Inc. (KBLB) announced today that numerous financial websites experienced a temporary disruption in their Company related data stream on October 7, 2010.

The data stream interruption was the result of the largest market makers changing trading platforms. “Apparently the largest market makers have decided to run their trades through the pink sheet system because of dramatic increases in OTCBB trading fees,” said CEO Kim Thompson. “The change had nothing to do with our corporate activity. We remain current on all of our filings and will of course remain a reporting company. Our third quarter just ended a few days ago on September 30th, and we anticipate filing our 10Q in record time for Kraig.”

The migration of market makers from the OTCBB to the Pink Sheet trading platform apparently began accelerating when the OTCBB decided to increase the fees it charges market makers. When market makers run their trades through a rival platform and give no part of their business in a security to the OTCBB for a period of four days or more, the OTCBB can list the subject security on its daily list under rule 15c2-11. For reasons which have not been explained by the OTCBB, this action resulted in the data stream disruption as the OTCBB did not bother to provide advance notice to the financial service websites, to the company or, apparently, even to its market makers.

During the disruption the Company publicized that current data might be obtained by adding .pk to the Company’s symbol. As of this writing, it appears that that is not necessary and that data flow has been restored to KBLB. The Company thanks all of the financial service websites and information technologies professionals who worked during the day to restore the flow of information.

As a reminder, the Company will be hosting a conference call today, Friday October 8, 2010 at 4:30 PM EDT. Please check our public announcement of earlier today for conference details.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com .

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact: Ben Hansel (720) 288-8495, benhansel@yahoo.com

LANSING, MI — (Marketwire) — 10/08/10 — Kraig Biocraft Laboratories, Inc. (KBLB) reminds all current, new and prospective shareholders that the Company’s CEO will conduct a shareholder conference call today, Friday, October 8, 2010 at 4:30 p.m. EDT.

Kim Thompson, the Company’s CEO and founder, will review the recent development of recombinant spider silk technology, the Company’s intellectual property and commercialization rights to this technology, as well as what is in the research and development pipeline.

Interested parties should dial the toll-free numbers below in the order provided. If the first number does not connect, please dial the next number below.

1. 866-906-9888 and when prompted enter access code 3535794 followed by the # (pound) sign.

2. 866-506-1209 and when prompted enter access code 3535794 followed by the # (pound) sign.

3. 866-939-8416 and when prompted enter access code 3535794 followed by the # (pound) sign.

It is recommended that callers dial in approximately five minutes before the conference is scheduled to begin.

Shareholders are invited to submit questions to benh@ttfsco.com prior to noon today. For interested parties who are unable to make today’s call, the Company anticipates posting a recording of the conference call on the Company website sometime in the near future.

All interested parties are encouraged by the Company to use the following link to view a video of the public announcement concerning the recent scientific breakthrough in order to be prepared for the conference call. http://www.youtube.com/watch?v=GnUupDb2Mvo

Additional information is available on Kraig Biocraft Laboratories web site: https://kraiglabs.com.

Conference call: 4:30 p.m. EDT (Eastern Daylight Time) today, Friday, October 8, 2010.

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact: Ben Hansel (720) 288-8495, benhansel@yahoo.com

LANSING, MI–October 5, 2010- Kraig Biocraft Laboratories, Inc. (KBLB) announced today that that it has filed intent to use applications with the US Patent and Trademark office seeking registration of numerous marks for the purpose of branding recombinant silk fibers.

“The Company views branding of our recombinant silk to be just as important as it is with any other product line. It is anticipated that the proposed marks will enhance product marketability and distinguish our advanced technology from other fibers in the marketplace,” said Kim Thompson, the Company’s CEO and founder. “This is just the beginning of the Company’s efforts to further distinguish itself in the market place as we move toward the commercialization of our technology.”

The intent to use applications included seven separate proposed marks including Spiderpillar™ and Monster Silk™.

The Company recently announced the successful development of recombinant spider silk based fibers using genetic engineering. A video of that press conference can be viewed on the Company web site or at http://www.youtube.com/watch?v=GnUupDb2Mvo

The Company will also hold a shareholder press conference on Friday, October 8, 2010 at 4:30 p.m. EDT and will issue a reminder press release the morning of the conference call, which will include the phone number and access code instructions.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com.

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel
(720) 288-8495
benh@ttfsco.com

LANSING, MI–October 1, 2010-  Kraig Biocraft Laboratories, Inc. (KBLB) announces today that Kim Thompson cordially invites all current, new and prospective shareholders to participate in the Company’s conference call to be held on Friday, October 8, 2010 at 4:30 p.m. EDT.

Thompson, the Company’s CEO and Founder, will review the recent development of recombinant spider silk, the Company’s intellectual property and commercialization rights to this powerful technology, as well as what is in the pipeline for near term research and development payoff, followed by a question and answer period.

The conference call phone number and other details will be announced in a follow-up company release early next week. Shareholders are invited to submit questions to benh@ttfsco.com prior to the event.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com.

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel
(720) 288-8495
benh@ttfsco.com

Kraig Exercises Option for Exclusive Commercial License

SOUTH BEND, IN — (Marketwire) — 09/30/10 — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) is very pleased to announce that a provisional patent application has been filed by the University of Notre Dame on the artificial spider silk technology revealed at the Company’s joint press conference yesterday with the University of Notre Dame. The patent filing covers all of the breakthrough technology revealed at the press conference, including artificial spider silk and the methods used to create transgenic silkworms capable of spinning artificial spider silk and recombinant fiber.

Pursuant to the provisions of Kraig Biocraft Laboratories collaborative research and intellectual property agreement with the University, the Company has an option for a global exclusive license to use the technology commercially. The Company is happy to inform its shareholders that it has now exercised that option.

“We built this company with this moment in mind. Our exclusive commercial license was essentially pre-negotiated at the time we entered into the collaborative research agreement,” explained CEO Kim Thompson. “The next few months will be a very exciting time for Kraig as we work toward our vision for commercialization of this new and exciting technology. We are rapidly moving from being exclusively research and development to entering a marketable product and deliverable biotechnology stage.”

For more information on the University’s view of this spider silk technology breakthrough you can visit http://newsinfo.nd.edu/ .

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: Ben Hansel (720) 288-8495